Measures of disease activity in glaucoma

Quantitative brain-derived neurotrophic factor lateral flow assay for point-of-care detection of glaucoma

“…InflammaDry is a commercially available LFA device designed to detect matrix metallopeptidase 9 (MMP-9) 9 in tear fluid. Sambursky et al demonstrated that the sensitivity and specificity of InflammaDry were 85% and 94%, respectively.…”

“…InflammaDry is a commercially available LFA device designed to detect matrix metallopeptidase 9 (MMP-9) 9 was 73% and positive predictive value was 97% 22 . Another group developed a LFA device to detect trachoma based on the antibody against Chlamydia trachomatis 60 .…”

“…Moreover, due to noninvasive accessibility 7 tear fluid provides an ideal platform for the biomarker detection of ocular diseases, including glaucoma. Many proteomics studies have investigated tear fluid to explore potential biomarkers for glaucoma and have demonstrated some candidates such as lysozyme C (LYZ), protein S100, immunoglobulins, prolactin-inducible protein, and phosphorylated cystatin-S (CST4) 8,9 . However, none of these biomarkers show strong correlations with glaucoma onset and/or progression, and their involvement in glaucoma disease activity still needs to be established.…”

“…Many proteomics studies have investigated tear fluid to explore potential biomarkers for glaucoma and have demonstrated some candidates such as lysozyme C (LYZ), protein S100, immunoglobulins, prolactininducible protein, and phosphorylated cystatin-S (CST4). 8,9 However, none of these biomarkers show strong correlations with glaucoma onset and/or progression, and their involvement in glaucoma disease activity still needs to be established. Brain-derived neurotrophic factor (BDNF) plays an important role in regulating the survival, development, function, and plasticity of the nervous system.…”

Updates in Clinical and Translational Glaucoma Research

“…Throughout the last decade, the interest in glaucoma diagnosis and therapy has been encouraged through outstanding biotechnological advances and the emergence of artificial intelligence to make the decision-making processes of glaucoma management easier [ 2 , 3 ]. Clinicians, biomedical engineers, and scientific researchers have been involved in improving knowledge of glaucoma risk factors and pathogenic mechanisms as well as refining innovative tools for glaucoma diagnostic performance, such as those wielded for corneal biomechanical properties, intraocular pressure (IOP) measurement, structural and functional glaucoma probes [ 4 , 5 , 6 , 7 , 8 , 9 ], and those regarding the discovery of IOP-lowering medical, laser, and surgical approaches [ 10 , 11 ].…”